Mitsuo Hori, MD from Ibaraki Prefectural Central Hospital discusses ELOQUENT-2 study in Japanese patients safety was consistent with patients in relapsed refractory myeloma at the 2017 American Society of Hematology.
ELOQUENT-2 Study in Japanese Patients – Safety was consistent with patients in relapsed refractory myeloma
